Paloma Partners’s Fate Therapeutics FATE Stock Holding History

Paloma Partners’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-31,100	Closed	-$631K	–	2048
2019 Q2	$631K	Buy	+31,100	New	+$560K	0.01%	918

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

Paloma Partners's FATE Position: Q3 2019 in Review

Paloma Partners sold out of Fate Therapeutics (FATE) in Q3 2019, closing a stake of 31,100 shares — an estimated $631K sold.

Paloma Partners first reported a position in FATE in Q2 2019 and held it in 1 quarter. The position peaked at $631K in Q2 2019. 149 funds tracked by Wall St. Rank hold FATE as of Q3 2019.

Paloma Partners reported no remaining Fate Therapeutics position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 31,100 Fate Therapeutics shares in Q3 2019, an estimated $631K.
Paloma Partners first reported a position in Fate Therapeutics in Q2 2019 and held it in 1 quarter.
Paloma Partners's Fate Therapeutics position peaked at $631K in Q2 2019.
149 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.